Ionis Pharmaceuticals (IONS)Officer sold ~$753K
Eugene Schneider, Officer at Ionis Pharmaceuticals, sold ~$753K of Ionis Pharmaceuticals shares.
- ~$753K
- Approx. value · 12K sh @ $60.46
- 59K
- Holds after · shares reported
- Traded
- Sep 3, 2025
- Filed
- Sep 5, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jul 11, 2025InsiderCEO sold ~$48K of IONS shares in the open market
- Jul 30, 2025InsiderCEO sold ~$109K of IONS shares in the open market
- Aug 4, 2025InsiderOfficer sold ~$409K of IONS shares in the open market
- Aug 5, 2025InsiderOfficer sold ~$429K of IONS shares in the open market
- Aug 6, 2025Insider · 1 personInsiders: 2 sales (~$210K)
- Aug 18, 2025InsiderOfficer sold ~$440K of IONS shares in the open market
- Aug 22, 2025InsiderDirector sold ~$61K of IONS shares in the open market
- Sep 2, 2025Insider · 6 peopleInsiders: 9 sales (~$4.0M)
- Sep 3, 2025 · this disclosureInsiderOfficer sold ~$753K of IONS shares in the open market
What came next
- Sep 3, 2025Insider · 9 peopleInsiders: 13 sales (~$24.9M)
- Sep 5, 2025Insider · 2 peopleInsiders: 2 sales (~$373K)
- Sep 9, 2025Insider · 2 peopleInsiders: 3 sales (~$2.1M)
- Sep 12, 2025InsiderOfficer sold ~$110K of IONS shares in the open market
- Oct 28, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
- Oct 29, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 11, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Ionis Pharmaceuticals
For Ionis Pharmaceuticals, OQRO holds 11 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IONS page.
Other recent filings by Eugene Schneider, EVP, Chf Clinical Develop Ofcr
- SEC Form 4 at Ionis Pharmaceuticals (IONS)Sep 5, 2025
- SEC Form 4 at Ionis Pharmaceuticals (IONS)Aug 5, 2025
- SEC Form 4 at Ionis Pharmaceuticals (IONS)Feb 4, 2025
- SEC Form 4 at Ionis Pharmaceuticals (IONS)Jan 18, 2025
The full history of Eugene Schneider, EVP, Chf Clinical Develop Ofcr is on the profile page.
How this filing works
Other disclosures at Ionis Pharmaceuticals
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its IONS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data